Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces that a Securities Class Action has been Filed Against Edwards

    Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces that a
  Securities Class Action has been Filed Against Edwards Lifesciences Corp.

PR Newswire

NEW YORK, Sept. 23, 2013

NEW YORK, Sept. 23, 2013 /PRNewswire/ --Bronstein, Gewirtz & Grossman, LLC
announces that a securities class action has been filed in the United States
District Court for the Central District of California on behalf of those who
purchased shares of Edwards Lifesciences Corporation. ("Edwards Lifesciences
or the Company") (NYSE: EW), during the period between April 25, 2012 and
April 23, 2013, inclusive (the "Class Period").

The complaint charges Edwards Lifesciences and certain of its executives with
violations of federal securities laws. The complaint alleges that during the
class period Edwards Lifesciences and certain of its executives issued a
series of materially false and misleading statements during the Class Period,
specifically the complaint alleges that the Company concealed from its
shareholders the following: (1) adoption of SAPIEN was weaker than the
Company claimed due to concerns among physicians over the risks and complexity
of the procedure for implanting the valve; (2) the Company's outlook for sales
and earnings per share was significantly weaker than the optimistic guidance
Defendants offered to investors; and (3) as a result, Defendants lacked a
reasonable basis for their statements concerning Edwards Lifesciences'
operations, forecasts, and outlook.

On April 24, 2013, shares of Edwards Lifesciences fell $18.21 of 21.99% to
close at $64.60 after the Company disclosed, after the market closed on April
23, 2013, that approximately 20 candidate hospitals had postponed SAPIEN
training, that there was substantially no backlog of patients awaiting SAPIEN
implants, and that the Company's financial results had been and would likely
continue to be weaker than estimates.

Plaintiff seeks to recover damages on behalf of all Edwards Lifesciences
shareholders who purchased common stock during the Class Period described
above.

No Class has yet been certified in the above action. If you wish to review a
copy of the Complaint, to discuss this action, or have any questions, please
contact Peretz Bronstein, Esq. or his Investor Relations Coordinator Eitan
Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email
info@bgandg.com. Those who inquire by e-mail are encouraged to include their
mailing address and telephone number. November 18, 2013 is the deadline for
investors to seek a lead plaintiff appointment. Your ability to share in any
recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our
primary expertise is the aggressive pursuit of litigation claims on behalf of
our clients. In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm's expertise includes
general corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not guarantee similar
outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com



SOURCE Bronstein, Gewirtz & Grossman, LLC

Website: http://www.bgandg.com
 
Press spacebar to pause and continue. Press esc to stop.